Search: onr:"swepub:oai:lup.lub.lu.se:6814bc18-aa01-4ffd-b682-e1da5f3ca0c9" >
Lenalidomide-bendam...
-
Albertsson-Lindblad, AlexandraLund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital
(author)
Lenalidomide-bendamustine-rituximab in untreated mantle cell lymphoma > 65 years, the Nordic Lymphoma Group phase I+II trial NLG-MCL4
- Article/chapterEnglish2016
Publisher, publication year, extent ...
-
American Society of Hematology,2016
-
electronicrdacarrier
Numbers
-
LIBRIS-ID:oai:lup.lub.lu.se:6814bc18-aa01-4ffd-b682-e1da5f3ca0c9
-
https://lup.lub.lu.se/record/6814bc18-aa01-4ffd-b682-e1da5f3ca0c9URI
-
https://doi.org/10.1182/blood-2016-03-704023DOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:art swepub-publicationtype
-
Subject category:ref swepub-contenttype
Notes
-
For elderly patients with mantle cell lymphoma (MCL), there is no defined standard therapy. In this multicenter open-label phase I/II trial we evaluated the addition of lenalidomide (LEN) to rituximab-bendamustine (R-B) as first-line treatment to elderly MCL patients. Patients >65 years with untreated MCL, stage II-IV were eligible for inclusion. Primary endpoints were maximally tolerable dose (MTD) of LEN, and progression-free survival (PFS). Patients received six cycles q4w of L-B-R (L D1-14, B 90 mg/m(2) iv D1-2 and R 375 mg/m(2) iv D1) followed by single LEN (D1-21, q4w, cycles 7-13). 51 patients (median age 71 years) were enrolled 2009-2013. In phase I, the MTD of LEN was defined as 10 mg in cycles 2-6, and omitted in cycle 1. After six cycles, the complete remission rate (CRR) was 64% and 36% were MRD negative. At a median follow-up time of 31 months, median PFS was 42 months and 3 year overall survival was 73%. Infection was the most common non-hematological grade 3-5 event and occurred in 21 (42%) patients. Opportunistic infections occurred in three patients; 2 PCP and 1 CMV retinitis. Second primary malignancies (SPM) were observed in eight patients (16%). LEN could safely be combined with R-B, when added from the second cycle in patients with MCL, and was associated with a high rate of CR and molecular remission. However, we observed a high degree of severe infections and an unexpected high number of SPMs which may limit its use. http://clinicaltrials.gov: NCT00963534.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Kolstad, ArneOslo university hospital
(author)
-
Laurell, AnnaUppsala University Hospital(Swepub:lu)onk-ala
(author)
-
Räty, RiikkaHelsinki University Central Hospital
(author)
-
Grønbæk, KirstenCopenhagen University Hospital
(author)
-
Sundberg, JanSkåne University Hospital
(author)
-
Pedersen, Lone BredoCopenhagen University Hospital
(author)
-
Ralfkiær, ElisabethCopenhagen University Hospital
(author)
-
Karjalainen-Lindsberg, Marja-LiisaUniversity of Helsinki,Helsinki University Central Hospital
(author)
-
Sundström, ChristerUppsala University
(author)
-
Ehinger, MatsLund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital(Swepub:lu)efor-meh
(author)
-
Geisler, ChristianCopenhagen University Hospital
(author)
-
Jerkeman, MatsLund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)onk-mje
(author)
-
TumörmikromiljöSektion I
(creator_code:org_t)
Related titles
-
In:Blood: American Society of Hematology128:14, s. 1814-18201528-00200006-4971
Internet link
Find in a library
-
Blood
(Search for host publication in LIBRIS)
To the university's database
- By the author/editor
-
Albertsson-Lindb ...
-
Kolstad, Arne
-
Laurell, Anna
-
Räty, Riikka
-
Grønbæk, Kirsten
-
Sundberg, Jan
-
show more...
-
Pedersen, Lone B ...
-
Ralfkiær, Elisab ...
-
Karjalainen-Lind ...
-
Sundström, Chris ...
-
Ehinger, Mats
-
Geisler, Christi ...
-
Jerkeman, Mats
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
- Articles in the publication
-
Blood
- By the university
-
Lund University